【摘要】 目的探讨(125)~I粒子植入联合支气管动脉化疗栓塞治疗非小细胞肺癌(NSCLC)的临床应用价值。方法 34例NSCLC患者,进行支气管动脉化疗栓塞治疗16例(A组),(125)~I粒子植入联合支气管动脉化疗栓塞治疗18例(B组),治疗后进行疗效评价及生存分析。结果 A、B两组治疗有效率分别75%和83.3%;中位生存时间分别为为7.4个月和12.6个月;6、12、24个月生存率分别为62.5%、37.5%、0%和83.3%、55.5%、22.2%,两组中位生存时间及6、12、24个月的生存率差异有统计学意义(P<0.05)。结论 (125)~I粒子植入联合支气管动脉化疗栓塞是NSCLC的一种有效治疗方法,可以延长患者的生存时间。更多还原

【Abstract】 Objective To evaluate the clinical efficacy of ¹²⁵Ⅰseed implantation combined with bronchial arterial infusion chemotherapy in the treatment of non-small cell lung carcinoma（NSCLC）.Methods A total of 34 patients with NSCLC were enrolled in this study between September 2007 and September 2009,and were allocated to Group A and Group B according to the self-imposed treatment.Group A were treated with BAI,and Group B were treated with the combination treatment of ¹²⁵Ⅰseed implantation plus BAI.Clinical effects and survival rate were estimated.Results 16 patients were in Group A and 18 in Group B.Complete response（CR）,partial response（PR）,stable disease（SD） and progressive disease（PD） were 0,12,3 and 1 in Group A and 2,13,3 and 0 in Group B,respectively.The effective rates（CR±PR%） were 75%in Group A and 83.3%in Group B.The median survival time were 7.4 months in Group A and 12.6 months in Group B.The 6-,12-and 24-survival rates were 62.5%,37.5%,0%in group A and 83.3%, 55.5%,22.2%in Group B respectively.Conclusion ¹²⁵Ⅰseed implantation combined with BAI±BAE is an effective and safe treatment for NSCLC.It can significantly prolong the patient’s survival time.更多还原